Article Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine Pedro M. Folegatti 1,* , Duncan Bellamy 1 , Rachel Roberts 1, Jonathan Powlson 1, Nick J. Edwards 1 , Catherine F. Mair 1, Georgina Bowyer 1 , Ian Poulton 1, Celia H. Mitton 1, Nicky Green 2, Eleanor Berrie 2, Alison M. Lawrie 1, Adrian V.S. Hill 1 , Katie J. Ewer 1 , John Hermon-Taylor 3 and Sarah C. Gilbert 1 1 The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK;
[email protected] (D.B.);
[email protected] (R.R.);
[email protected] (J.P.);
[email protected] (N.J.E.);
[email protected] (C.F.M.);
[email protected] (G.B.);
[email protected] (I.P.);
[email protected] (C.H.M.);
[email protected] (A.M.L.);
[email protected] (A.V.S.H.);
[email protected] (K.J.E.);
[email protected] (S.C.G.) 2 Clinical BioManufacturing Facility, Churchill Hospital, University of Oxford, Oxford OX3 7JT, UK;
[email protected] (N.G.);
[email protected] (E.B.) 3 Department of Nutritional Sciences, Faculty of Life Sciences & Medicine, Franklin Wilkins Building, King’s College London, London SE1 9NH, UK;
[email protected] * Correspondence:
[email protected] Received: 11 March 2019; Accepted: 8 May 2019; Published: 15 May 2019 Abstract: Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens.